Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Oncology

Articles with lock require a GLG News subscription
Posted May 5, 2008
Micromet Enrolls First Patient in Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Analysis of: Micromet Enrolls First Patient in Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors | www.pipelinereview.com
Author: GLG Member Program Contributor
Micromet's Bite antibodies strategy garners the patient's T-cells to attack tumor cells. This technology showed proof of principle i hematological malignancies , and now a Phase I clinical trial has commenced for solid tumors. The rationale is intriguing, but immunotherapy has been elusive in solid...
Posted April 30, 2008
Data suggests promising overall survival and progression-free survival with Vargatef(TM) (BIBF 1120)
Analysis of: Data suggests promising overall survival and progression-free survival with Vargatef(TM) (BIBF 1120) | www.pipelinereview.com
Author: GLG Member Program Contributor
This study is notable for several reasons: (1) it looked at 2 dose of BIBF 1120 and found essentially no difference in tumor control between the higher and lower dose regimens; (2) it included only patients who had previously received chemotherapy, and therefore, by definition, were less likely to have...
Posted April 28, 2008
Micromet Enrolls First Patient in Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Analysis of: Micromet Enrolls First Patient in Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors | www.pipelinereview.com
Author: GLG Member Program Contributor
Antibodies are formed by the bodies own immune system to any foreign substances it encounters. Tumors are considered by the body to be foreign at it often requires a genetic mutation for cells to become cancerous. Cancers are able to circumvent these natural antibodies by various means but there is...
Posted April 24, 2008
Poniard reports positive results for lung cancer drug
Analysis of: Poniard reports positive results for lung cancer drug | www.cnbc.com
Author: GLG Member Program Contributor
Doubles survival BUT "comparator" arm is best supportive care. See http://investor.poniard.com/ReleaseDetail.cfm?ReleaseID=306218
Donald Fleming Posted April 21, 2008
Why Xeloda can't eliminate 5FU
Analysis of: Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer | jco.ascopubs.org
Author: Donald Fleming, Division Head of Hematology and Oncology Davis Health System, Inc.
Xeloda has time after time demonstrated to be as good if not better than 5FU Xeloda continues to lag behind 5FU in the US Recent trial results are not likely to change things overnight
Posted April 21, 2008
ASA404 begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death
Analysis of: ASA404 begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death | www.pipelinereview.com
Author: GLG Member Program Contributor
Novartis has a leading pipeline in cancer drugs and has staked their profits on the cancer market more than any of the major drug makers. The drug in question (ASA404) is a Non-small cell lung cancer treatment candidate, This cancer accounts for up to 90% of all lung cancers. Worldwide, lung cancer...
Posted April 21, 2008
New Phase III Data Confirm Phase II Findings of Advexin Efficacy
Analysis of: New Phase III Data Confirm Phase II Findings of Advexin Efficacy | pharmalive.com
Author: GLG Member Program Contributor
The p53 tumor suppressor gene is though to be a in-built protective agent for cells against their transforming into cancer cells. Loss of this gene during the cell’s life predisposes it to become cancerous. Potential therapies that may stop or reverse this loss of protection, may be beneficial in cancer...
Posted April 21, 2008
Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
Analysis of: Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer | jco.ascopubs.org
Author: GLG Member Program Contributor
Xeloda, an oral agent, was non-inferior to infusional 5-FU, when combined ith oxaliplatin in a randomized trial in patients with metastatic colrectal cancer (m-CRC) In fact, Xeloda containing regimen was assocaited with less myelosuppression, but more rashes and diaarhea. This is good news for...
Posted April 18, 2008
Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
Analysis of: Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer | jco.ascopubs.org
Author: GLG Member Program Contributor
In MCRC FOLFOX which involves infusional 5FU has been the cornerstone of therapy. This study shows that an oral 5FU substitute, Xeloda, can replace the IV 5FU and expedide care and avoid cumbersome infusions.
Donald Fleming Posted April 16, 2008
Non small cell lung cancer has little to be excited about
Analysis of: ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer | www.pipelinereview.com
Author: Donald Fleming, Division Head of Hematology and Oncology Davis Health System, Inc.
Lilly will likely get front line approval for Alimta in non small cell lung cancer Most patients with advanced disease never see a response to therapy
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next101 to 110 of 722

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-08-29T09:45:18.400